{
    "case_number": "CAC-UDRP-107918",
    "time_of_filling": "2025-09-08 11:13:25",
    "domain_names": [
        "truxima.cc"
    ],
    "case_administrator": "Olga Dvořáková (Case admin)",
    "complainant": [
        "Celltrion, Inc."
    ],
    "complainant_representative": "SILKA AB",
    "respondent": [
        "abdul hameed (medu)"
    ],
    "respondent_representative": null,
    "factual_background": "<p>The Complainant is a Korean global integrated biotechnology company involved in the research, development and production of biosimilars, biodrugs, and chemical drugs. The Complainant has more than 3,000 employees and is the largest manufacturer and exporter of biosimilars in the Republic of Korea, with its products being sold in over 100 countries worldwide, and currently having a market capitalization of around USD 29 billion. Among the biosimilar monoclonal antibodies developed and produced by the Complainant and sold around the world, its TRUXIMA branded product is a biosimilar of rituximab for the treatment of adults with non-Hodgkin&rsquo;s lymphoma and rheumatoid arthritis. On February 17, 2017, TRUXIMA received a marketing authorization from the European Medicines Agency valid throughout the European Union. In 2018, the United States Food and Drug Administration approved TRUXIMA for the treatment of non-Hodgkin's lymphoma, and in 2019 for the treatment of rheumatoid arthritis.<\/p>\n<p>&nbsp;<\/p>\n<p>The Respondent registered the disputed domain name on May 6, 2025. The disputed domain name is passively held and has MX servers configured.<\/p>",
    "other_legal_proceedings": "<p>The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the disputed domain name.<\/p>",
    "no_response_filed": "<p>The Complainant contends that the requirements of the Policy have been met and that the disputed domain name should be transferred to it.<\/p>\n<p><span>No administratively compliant Response has been filed.<\/span><\/p>",
    "rights": "<p>The Complainant has, to the satisfaction of the Panel, shown the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/p>",
    "no_rights_or_legitimate_interests": "<p>The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the Policy).<\/p>",
    "bad_faith": "<p>The Complainant has, to the satisfaction of the Panel, shown the disputed domain name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/p>",
    "procedural_factors": "<p>The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>",
    "decision": "Accepted",
    "panelists": [
        "Alfred Meijboom"
    ],
    "date_of_panel_decision": "2025-10-05 00:00:00",
    "informal_english_translation": "<p>The Complainant is the owner of the TRUXIMA trademark, registered worldwide, including:<\/p>\n<ul>\n<li>International trademark TRUXIMA with registration number 1254346, registered on February 27, 2015, for goods in class 5, designating,<em> inter alia<\/em>, People's Republic of China, Russian Federation and Japan;<\/li>\n<li>United States trademark TRUXIMA with registration number 4962045, registered on May 24, 2016, for goods in class 5; and<\/li>\n<li>International stylized trademark TRUXIMA with registration number 1853192, registered on March 7, 2025 for goods in class 5, designating Bosnia and Herzegovina, Canada, Malaysia, Philippines, Pakistan, Serbia, and Viet Nam.<\/li>\n<\/ul>",
    "decision_domains": {
        "truxima.cc": "TRANSFERRED"
    },
    "panelist": null,
    "panellists_text": null
}